Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

439743

registered interest
date	22/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dermatology: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government how many of the Clinical Commissioning Groups in England and Wales have prevented access to dermatology specials for their patients on the grounds of cost in the last five years.
tabling member printed	Lord Hunt of Kings Heath
uin	HL4796
answer	answer is ministerial correction date of answer 04/01/2016 answer text <p>This information is not collected centrally.</p> answering member printed Lord Prior of Brampton question first answered 04/01/2016 14:17:47 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

439744

registered interest
date	22/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Wound Dressings: Procurement
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what account they will take of the representations by the Wound Care Alliance UK regarding the NHS Supply Chain generic project plans for a national formulary for wound care.
tabling member printed	Lord Hunt of Kings Heath
uin	HL4797
answer	answer is ministerial correction date of answer 04/01/2016 answer text <p>The NHS Supply Chain is co-ordinating the production of clinical specifications by a Clinical Specifications Working Group, who are representing their customers in capacity of experts in wound care. This group, the Clinical Specifications Working Group, is independent of the NHS Supply Chain set up by the Clinical Reference Board.</p><br /><p>The Clinical Specification Working Group has engaged with various stakeholders, including the Tissue Viability Society, in the process and will ultimately approve the resultant specifications.</p> answering member printed Lord Prior of Brampton question first answered 04/01/2016 13:57:23 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

439745

registered interest
date	22/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Wound Dressings: Procurement
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether educational and patient-orientated organisations were involved in the planning of the NHS Supply Chain generic project plans for a national formulary for wound care.
tabling member printed	Lord Hunt of Kings Heath
uin	HL4798
answer	answer is ministerial correction date of answer 04/01/2016 answer text <p>The Clinical Specification Working Group has academic representation on the group from England and Wales. Patient orientated organisations may be involved, as appropriate, at an evaluation stage though they have not engaged with them at this point.</p> answering member printed Lord Prior of Brampton question first answered 04/01/2016 14:04:22 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

439746

registered interest
date	22/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Wound Dressings: Procurement
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government how they plan to ensure that, in the implementation of the NHS Supply Chain generic project plans for a national formulary for wound care, innovative small companies are not at a disadvantage in bidding for contracts.
tabling member printed	Lord Hunt of Kings Heath
uin	HL4799
answer	answer is ministerial correction date of answer 04/01/2016 answer text <p>Innovation is welcomed as part of this process and the clinical specifications may support smaller companies who demonstrate their capability to meet the requirements. One advantage of the NHS Supply Chain venture for smaller companies is that it can act as a single point of entry into the National Health Service and lower the ‘cost of sales’.</p> answering member printed Lord Prior of Brampton question first answered 04/01/2016 14:05:09 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

439747

registered interest
date	22/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Wound Dressings: Procurement
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of the clinical and ethical justifications for setting the benchmark in the NHS Supply Chain generic project plans for a national formulary for wound care that 80 per cent of patients will be treated using clinically appropriate dressings.
tabling member printed	Lord Hunt of Kings Heath
uin	HL4800
answer	answer is ministerial correction date of answer 04/01/2016 answer text <p>The wide variety of choice in the current system is leading to duplication of wound care products. This can create more complexity for nurses and clinicians, making their clinical decisions more difficult and potentially leading to over specification and variation in standards of care. Of the 4,796 wound care products available through the NHS Supply Chain, 34% of lines have had no sales in the last 12 months.</p><br /><p>Providing an agreed set of National Health Service requirements for wound care products will start to reduce this duplication, complexity and therefore potential risk, helping to improve patient outcomes through less variation in care.</p><br /><p>This issue was also highlighted by 74% of respondents to a Royal College of Nursing survey run by Nursing Times (Dec 2014) seeing opportunities to reduce duplication on wound care products, (more than any other type of product).</p><br /><p>The project is part of a wider piece of work the Department is working with the NHS Supply Chain on to deliver £300 million of savings by October 2018. Central to this is reducing the number of specifications and variations by category so the NHS can leverage its scale and deliver clinically appropriate solutions that represent ‘value for money’. Such approaches are common in other countries and help drive savings, improve clinical standards and protect front line nursing.</p> answering member printed Lord Prior of Brampton question first answered 04/01/2016 14:24:42 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

439748

registered interest
date	22/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Wound Dressings: Procurement
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what plans they have to monitor the impact of the introduction of the NHS Supply Chain generic project plans for a national formulary for wound care.
tabling member printed	Lord Hunt of Kings Heath
uin	HL4801
answer	answer is ministerial correction date of answer 04/01/2016 answer text <p>The NHS Supply Chain can provide data analysis on the usage of products procured through their route.</p><br /><p>Incidents raised through the use of the products would be monitored by individual NHS trust clinical staff and appropriate investigations would be instigated.</p><br /> answering member printed Lord Prior of Brampton question first answered 04/01/2016 14:03:57 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

439760

registered interest
date	22/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Biosimilar Medicines: Prescriptions
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government which organisation has responsibility for ensuring implementation and compliance with the Medicines and Healthcare products Regulatory Agency guidance, which states that biologic medicines should be prescribed by brand name and tracked by batch number.
tabling member printed	Baroness Brinton
uin	HL4813
answer	answer is ministerial correction date of answer 05/01/2016 answer text <p>In 2008, the Medicines and Healthcare products Regulatory Agency (MHRA) issued best practice guidance on the prescribing of biological products. This advised:</p><br /><p>“All biosimilar products are prescription only medicines (POM). When prescribing biological products, it is good practice to use the brand name. This will ensure that automatic substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Products (biosimilar and reference) that have the same international non-proprietary name (INN) are not to be presumed identical for the reasons given above.”</p><br /><p>The MHRA does not have responsibility for monitoring the compliance of healthcare professionals with its prescribing guidance. The responsibility for prescribing rests with the practitioner who has clinical responsibility for their patient's care and we would expect practitioners to take any relevant guidance into account when making their prescribing decisions. Practitioner professional bodies also have a role in setting out best practice to their members.</p> answering member printed Lord Prior of Brampton question first answered 05/01/2016 10:12:27 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4241 label Biography information for Baroness Brinton

439692

registered interest
date	21/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Care Homes
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 19 November (HL3562), in the absence of centrally collected data on the occupancy levels of registered care homes, on what data the Care Quality Commission relies to discharge its oversight function for the publicly-funded nursing and residential care sectors.
tabling member printed	Lord Warner
uin	HL4768
answer	answer is ministerial correction date of answer 05/01/2016 answer text <p>The purpose of market oversight, amongst other things, is to protect people who may be placed in vulnerable circumstances due to the failure of a ‘difficult to replace’ adult social care provider. It does this by monitoring in arrears the quarterly financial returns of those providers captured by the scheme. Since inclusion in the scheme is a reflection of provider size, by definition it is the larger providers that are captured by the scheme and as such market oversight is concerned with the overall consolidated financial performance. Consequently, it would not ordinarily consider occupancy levels for individual registered care homes.</p><br /><p>The types of information the Care Quality Commission collects from registered care providers as part of its Market Oversight Scheme is included in published guidance - <em>Market Oversight of ‘difficult to replace’ providers of adult social care</em>. The guidance is attached.</p> answering member printed Lord Prior of Brampton question first answered 05/01/2016 11:40:17 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name 20150327_market_oversight_full_guide_providers.pdf title Market Oversight Guidance
tabling member	1732 label Biography information for Lord Warner

439693

registered interest
date	21/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Care Homes
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 23 November (HL3565), what advice they will give to local authorities affected by significant withdrawal of residential care providers in particular areas from publicly-funded adult social care in the event that this prevents those authorities from stepping in to ensure people's needs.
tabling member printed	Lord Warner
uin	HL4769
answer	answer is ministerial correction date of answer 05/01/2016 answer text <p>The Government has worked with the Association of Directors of Adult Social Services (ADASS) and the Local Government Information Unit to publish guidance to support local authorities to develop effective contingency plans for provider failure- <em>Care and Continuity: Contingency planning for provider failure</em>. The guidance is attached.</p><br /><p>It is expected that local authorities will keep these plans under review and update them as necessary to reflect current market conditions and risks.</p><br /><p>Should there be a significant withdrawal of residential care providers from the publically funded adult social care market putting pressure on local authorities’ capacity to discharge their statutory functions in the short-term, the Government will work with the sector to develop bespoke contingency plans to support local government to manage the situation. This could include supporting work with neighbouring local authorities and ADASS regional networks.</p><br /><p>More widely, the Government will continue to support local authorities to discharge their functions under the Care Act 2014 which require them to shape a sustainable market that meets the needs of their local population.</p> answering member printed Lord Prior of Brampton question first answered 05/01/2016 12:25:12 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name Care-ContinuityFINAL.pdf title Contingency Planning for Provider Failure
tabling member	1732 label Biography information for Lord Warner

439694

registered interest
date	21/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Social Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment the Department of Health or NHS England has made of the risk of the wide-scale withdrawal of adult social care providers from publicly-funded social care markets and the implications of such a withdrawal for the NHS; and whether such a possible withdrawal features on the Department of Health risk register.
tabling member printed	Lord Warner
uin	HL4770
answer	answer is ministerial correction date of answer 05/01/2016 answer text <p>The Department monitors a number of risks to the health and social care system through its high level risk register, including the availability of good quality adult social care that is affordable for local authority and National Health Service commissioners.</p><br /><p>The Department is working with local authorities, NHS England, the Care Quality Commission and the provider sector to understand the extent of this risk and its potential drivers, which will include consideration of the extent to which some providers are possibly withdrawing from the publically funded adult social care market.</p><br /><p>The Care Act (2014) places duties on local authorities to step in and ensure people’s needs continue to be met if a provider fails financially and services cease. The Department has worked with the Association of Directors of Adult Social Services and the Local Government Information Unit to publish guidance to support local authorities develop effective contingency plans for provider failure - <em>Care and Continuity: Contingency planning for provider failure</em>. The guidance is attached. The guidance recommends that contingency plans are co-produced with relevant partners, including NHS Clinical Commissioning Groups to ensure these plans are aligned.</p><br /><p>Local authorities routinely manage market exits in their area and discharge their Care Act duties. If a situation arose that local authorities found challenging, for example because of its scale and the lack of spare capacity in the area, the Department would work with partners to support them.</p> answering member printed Lord Prior of Brampton question first answered 05/01/2016 11:41:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name Care-ContinuityFINAL.pdf title Contingency Planning for Provider Failure
tabling member	1732 label Biography information for Lord Warner